Skip to main content

Only DUPIXENT targets IL-4Rα, specifically inhibiting IL-4 and IL-13 signaling1,2

Dual inhibition of IL-4 and IL-13 signaling helps:

REDUCE TYPE 2 INFLAMMATION1,3

REDUCE ITCH1-3

  • Helps relieve itch-scratch cycle
  • May reduce neuronal sensitization

ACHIEVE NODULE
CLEARANCE1,4-6

Helps reduce skin fibrosis

The mechanism of dupilumab action has not been definitively established.

IL-4 and IL-13 signaling leads to the itch-scratch cycle and formation of nodules

IL-4 is an orchestrator of Th2 responses, and both IL-4 and IL-13 contribute to the signs and symptoms of PN4-12

Diagram of type 2 cytokines creating a closed positive feedback loop

IL-4 creates a feedback loop that leads to increased secretion of IL-4, IL-13, and IL-317,b,c

aIncluding Th2, Th17, and Th22 cells, eosinophils, and basophils.

bType 2 cytokines (such as IL-4, IL-13, and IL-31) may also be produced by other immune cells, such as ILC2.13,14

cIL-4 acts on both type I and type II receptors to mediate type 2 inflammation.2

DUPIXENT binds to IL-4Rα, inhibiting IL-4 and IL-13 induced inflammatory responses1,2

The mechanism of dupilumab action has not been definitively established.
Diagram of Dupixent® (dupilumab) inhibiting IL-4 and IL-13 signaling
IL-4 is an orchestrator of Th2 responses15-20
  • IL-4 is required for differentiation of Th2 cells from the naive T cellsa
  • IL-4 creates a positive feedback loop to produce more Th2 cells
  • Th2 cells release type 2 cytokines (IL-4, IL-13, IL-31)b
  • DUPIXENT helps reduce the production of type 2 cytokines and inflammatory mediators

aSeveral cells act as an early source of IL-4 (eg, basophils and dendritic cells) in a cascade triggered by environmental and genetic factors.7,18

bType 2 cytokines (such as IL-4, IL-13, and IL-31) may also be produced by other immune cells, such as ILC2.13,14

Assess when your patients might be ready for DUPIXENT

IDENTIFYING PATIENTS

PN, prurigo nodularis.